Skip to content
Dosavy
No account · No paywall · Last changed 20 September 2026

Compound evidence ledger

Every dose we show links to its paper. 15 of the 35 compounds in this table have no published human dose, and the table says which; across the whole library it is 18 of 50. Each row carries the evidence status, the level of the best study behind it, the regulatory status, and the sources behind its cited doses and reviewed interactions, numbered where the compound’s page uses them.

Cited human dosesNo human dosing dataNot studiedHow these labels are decided
01Ledger
CompoundClassDosing evidenceBest evidenceRegulatorySourcesLast changed
5-Amino-1MQLongevityNo human dosing dataAnimal data onlyResearch use onlyNo cited dose or interaction2026-09-19
AOD-9604OtherNo human dosing dataLimited human dataResearch use onlyNo cited dose or interaction2026-09-19
BPC-157Healing peptideNo human dosing dataLimited human dataResearch use only
1 source
  1. PMID 41966639: Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
2026-09-20
CagrilintideGLP-1Cited human dosesRandomised trialsNot approved
4 sources
  1. PMID 34798060: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
  2. PMID 33894838: Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
  3. PMID 40544433: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
  4. PMID 42251859: Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
2026-09-03
CJC-1295 with DACGH secretagogueNo human dosing dataLimited human dataResearch use only
2 sources
  1. PMID 41476424: Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
  2. PMID 41880199: A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
2026-09-19
CJC-1295 without DACGH secretagogueNo human dosing dataAnimal data onlyResearch use only
2 sources
  1. PMID 41476424: Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
  2. PMID 41880199: A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
2026-09-19
DSIP (Delta Sleep-Inducing Peptide)Sleep / nootropicCited human dosesLimited human dataNot approved
6 sources
  1. PMID 25739189: [Using deltalicin for the treatment of patients with diabetic retinopathy]
  2. PMID 7777652: Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion
  3. PMID 1299794: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
  4. PMID 6895513: Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
  5. PMID 8475226: Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women
  6. PMID 19142086: Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
2026-09-19
EpithalonLongevityNo human dosing dataLimited human dataResearch use onlyNo cited dose or interaction2026-09-19
GHK-CuHealing peptideNo human dosing dataLimited human dataResearch use onlyNo cited dose or interaction2026-09-20
GHRP-2GH secretagogueNo human dosing dataLimited human dataResearch use only
1 source
  1. PMID 7586605: GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers
2026-09-19
GHRP-6GH secretagogueCited human dosesLimited human dataNot approved
3 sources
  1. PMID 7617137: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.
  2. PMID 2108187: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
  3. PMID 8473389: Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity
2026-09-03
GlutathioneLongevityCited human dosesRandomised trialsNot approved
7 sources
  1. PMID 24791752: Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
  2. PMID 39444151: Glutathione as a skin-lightening agent and in melasma: a systematic review
  3. PMID 26262996: Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study
  4. PMID 26230671: A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease
  5. PMID 8938817: Reduced intravenous glutathione in the treatment of early Parkinson's disease
  6. PMID 31399448: Glutathione infusion before primary percutaneous coronary intervention: a randomised controlled pilot study
  7. PMID 7799029: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial
2026-09-19
IGF-1 LR3HormoneNo human dosing dataAnimal data onlyResearch use only
1 source
  1. PMID 37579214: Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry
2026-09-03
IpamorelinGH secretagogueNo human dosing dataLimited human dataResearch use only
1 source
  1. PMID 41880199: A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
2026-09-19
KisspeptinHormoneCited human dosesRandomised trialsResearch use only
3 sources
  1. PMID 21632807: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
  2. PMID 23153270: Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism
  3. PMID 30590872: Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men
2026-09-19
KPVHealing peptideNo human dosing dataAnimal data onlyResearch use onlyNo cited dose or interaction2026-09-19
MK-677 (Ibutamoren)GH secretagogueCited human dosesRandomised trialsNot approved
5 sources
  1. PMID 8954023: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
  2. PMID 10404019: Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
  3. PMID 18981485: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
  4. PMID 19015485: Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
  5. PMID 9467542: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
2026-09-03
MOTS-cLongevityNo human dosing dataAnimal data onlyResearch use onlyNo cited dose or interaction2026-09-20
NAD+LongevityCited human dosesLimited human dataNot approved
4 sources
  1. PMID 40954388: Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial
  2. PMID 42514320: Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis
  3. PMID 36482258: The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
  4. PMID 39531138: Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials
2026-09-19
OrforglipronGLP-1Cited human dosesRandomised trialsApproved
3 sources
  1. FOUNDAYO (orforglipron) tablets, for oral use: FDA prescribing information
  2. WEGOVY (semaglutide) injection, for subcutaneous use: FDA prescribing information
  3. ZEPBOUND (tirzepatide) injection, for subcutaneous use: FDA prescribing information
2026-09-03
OxytocinHormoneCited human dosesRandomised trialsApproved
5 sources
  1. Oxytocin Injection, USP (synthetic): FDA prescribing information
  2. PMID 14675803: Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress
  3. PMID 33982141: Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial
  4. PMID 38815173: Intranasal Oxytocin for Obesity
  5. PMID 25503617: Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability
2026-09-03
Pentadeca ArginateHealing peptideNot studiedNot gradedResearch use onlyNo cited dose or interaction2026-09-19
PT-141OtherCited human dosesRandomised trialsApproved
4 sources
  1. VYLEESI (bremelanotide) injection, for subcutaneous use: FDA prescribing information
  2. PMID 14999221: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
  3. PMID 18206919: Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study
  4. PMID 14963471: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
2026-09-03
RetatrutideGLP-1Cited human dosesRandomised trialsNot approved
5 sources
  1. PMID 37366315: Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
  2. PMID 37385280: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
  3. PMID 42250575: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
  4. WEGOVY (semaglutide) injection, for subcutaneous use: FDA prescribing information
  5. ZEPBOUND (tirzepatide) injection, for subcutaneous use: FDA prescribing information
2026-09-03
SelankSleep / nootropicNo human dosing dataLimited human dataNot approvedNo cited dose or interaction2026-09-19
SemaglutideGLP-1Cited human dosesRandomised trialsApproved
4 sources
  1. OZEMPIC (semaglutide) injection, for subcutaneous use: FDA prescribing information
  2. WEGOVY (semaglutide) injection, for subcutaneous use: FDA prescribing information
  3. RYBELSUS / OZEMPIC (semaglutide) tablets, for oral use: FDA prescribing information
  4. ZEPBOUND (tirzepatide) injection, for subcutaneous use: FDA prescribing information
2026-09-03
SemaxSleep / nootropicCited human dosesLimited human dataNot approved
4 sources
  1. PMID 11517472: [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]
  2. PMID 29798983: [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]
  3. PMID 18379501: [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]
  4. PMID 39166935: [Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke]
2026-09-03
SermorelinGH secretagogueCited human dosesLimited human dataPrescription only
1 source
  1. PMID 1379256: Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
2026-09-19
SS-31 (Elamipretide)LongevityCited human dosesRandomised trialsApproved
4 sources
  1. PMID 37268435: Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
  2. PMID 33077895: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
  3. PMID 38602181: Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
  4. PMID 32096613: A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
2026-09-03
SurvodutideGLP-1Cited human dosesRandomised trialsNot approved
6 sources
  1. PMID 38330987: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
  2. PMID 38857788: Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
  3. PMID 42253238: Survodutide Once Weekly for the Treatment of Adults with Obesity
  4. PMID 38095657: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
  5. PMID 38847460: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
  6. ZEPBOUND (tirzepatide) injection, for subcutaneous use: FDA prescribing information
2026-09-03
TB-500Healing peptideNo human dosing dataAnimal data onlyResearch use onlyNo cited dose or interaction2026-09-19
TesamorelinGH secretagogueCited human dosesRandomised trialsApproved
3 sources
  1. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: FDA prescribing information
  2. PMID 20101189: Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
  3. PMID 16052083: A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
2026-09-03
TesofensineOtherCited human dosesRandomised trialsNot approved
4 sources
  1. PMID 18950853: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
  2. PMID 17324246: Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease
  3. PMID 35294397: Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
  4. PMID 24239329: Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET
2026-09-03
Thymosin Alpha-1OtherCited human dosesRandomised trialsNot approved
11 sources
  1. PMID 10607256: Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study
  2. PMID 15482167: Thymalfasin for the treatment of chronic hepatitis B
  3. PMID 22233415: Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
  4. PMID 26094695: A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol
  5. PMID 10759236: A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B
  6. PMID 39814420: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
  7. PMID 35713670: Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial
  8. PMID 17376268: [Effects of thymosin-alpha1 on cell immunity function in patients with septic shock]
  9. PMID 19278581: [Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patients with severe sepsis: a prospective, randomized, controlled clinical trial]
  10. PMID 14632754: A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy
  11. PMID 20549321: Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study
2026-09-03
TirzepatideGLP-1Cited human dosesRandomised trialsApproved
2 sources
  1. MOUNJARO (tirzepatide) injection, for subcutaneous use: FDA prescribing information
  2. ZEPBOUND (tirzepatide) injection, for subcutaneous use: FDA prescribing information
2026-09-03

15 prescription-only or controlled compounds are in the app and deliberately have no public page. A calculator page for one of them reads as instructions for self-administering a prescription medicine, which is the one thing this site is not. The line is prescription-only or controlled, not approved versus unapproved: an investigational compound gets a page, carrying whatever evidence status it actually has.

02Changelog

What changed, and when

  1. 20 September 2026

    Attribution pass on the records with no human dosing evidence: every sentence that still carried a dose number without saying where it came from now names its source in the same sentence, so a vendor or clinic figure cannot be read as a study dose. No figure, status or citation changed.

    BPC-157, GHK-Cu, MOTS-c

  2. 19 September 2026

    Prose pass: schema field and enum names that had been printed verbatim are reworded into plain English in the notes and warnings; kisspeptin no longer names a withheld compound; intravenous added to the routes of nad and glutathione to match their cited ranges; kpv's uncited subcutaneous route removed. No figure, status or citation changed.

    5-Amino-1MQ, AOD-9604, BPC-157, CJC-1295 with DAC, CJC-1295 without DAC, DSIP (Delta Sleep-Inducing Peptide), Epithalon, GHK-Cu, GHRP-2, Glutathione, Ipamorelin, Kisspeptin, KPV, MOTS-c, NAD+, Pentadeca Arginate, Selank, Sermorelin, TB-500

  3. 3 September 2026

    Punctuation pass across every record. No figure, status or citation changed.

    Every record

  4. 2 September 2026

    Semaglutide gains the boxed and label warnings it was missing (pancreatitis, gallbladder disease, hypoglycaemia with insulin, aspiration under anaesthesia, retinopathy and others); tirzepatide gains the retinopathy caveat.

    Semaglutide, Tirzepatide

  5. 28 August 2026

    CJC-1295 split into its two molecules, with and without DAC, each with its own record.

    CJC-1295 with DAC, CJC-1295 without DAC

  6. 2 August 2026

    Initial curation from the Stage 2 packets: evidence status, cited ranges, interactions and stacks for every compound.

    Every record

03What these are

Mixing math, not dosing advice

A compound page prefills two numbers: how much peptide the vial holds and how much Bacteriostatic Water to add. Both describe the vial. Neither is a target dose, and no page on this site fills one in for you. A number sitting in a field under a compound’s name gets read as that compound’s dose no matter what the label above it says.

What each page does state is the evidence: half-life, routes, storage, regulatory status, the published ranges where a human trial has produced one, and the papers behind every figure. Where no trial has, that gap is printed at the top of the page in the largest type on the screen rather than buried under a calculator.

The arithmetic is the same code that runs in the general reconstitution calculator and inside the app, so a draw volume cannot differ between them.